| Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer | NCT02751918 | I | Bayer |
| Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment | NCT02696642 | I | Bayer |
| Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | NCT02824042 | I | Bayer |
| Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | NCT02610140 | I | Bayer |
| Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | NCT02639091 | I | Bayer |
| Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma | NCT02839681 | II | National Cancer Institute (NCI) |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | NCT02485119 | I | Bayer |
